The Chair of the INTREPID Alliance’s Scientific Advisory Board, Dr. Ruxandra Draghia-Akli, delivered remarks at the opening session of the International Arbovirus Summit hosted by GISAID and the Ministries of Health for Brazil and Indonesia.
There are barely any therapeutics, vaccines, and diagnostics in the clinical pipeline for diseases with pandemic potential.
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts
As leaders and health experts from across the world gather in New York for the UN General Assembly, they will be considering three issues that are critical to the future of global health and global health security.
The INTREPID Alliance has abandoned its fundraising plans, but not its mission to expedite antiviral development for future pandemics.
An alliance of seven R&D-based pharma firms is putting collaboration and partnerships at the center of the search for new antivirals against emerging pathogens.
Seven innovative pharmaceutical companies have established the INTREPID Alliance, with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.